Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States

Dec 03 2001

• By The Pink Sheet

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

Related Content

Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients

Oct 22 2001

Xigris Best-Case Label Would Be 400,000 Patients; User Fee Date Is Oct. 27

Oct 22 2001

Syncor Xigris Delivery For Lilly Is First Non-Radiopharmacy Agreement

Aug 27 2001

Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA

Nov 26 2001

Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients

Dec 03 2001

FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy

Sep 17 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window